Novogen Limited Company Profile (NASDAQ:NVGN)

About Novogen Limited

Novogen Limited logoNovogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate. It focuses on various cancers, including melanoma and prostate cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: NVGN
  • CUSIP:
Key Metrics:
  • Previous Close: $1.70
  • 50 Day Moving Average: $1.63
  • 200 Day Moving Average: $1.75
  • 52-Week Range: $1.39 - $2.85
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -86.00
  • P/E Growth: 0.00
  • Market Cap: $29.57M
  • Outstanding Shares: 17,189,000
  • Beta: -0.21
Debt:
  • Current Ratio: 23.86%
  • Quick Ratio: 23.86%
Additional Links:
Companies Related to Novogen Limited:

Analyst Ratings

Consensus Ratings for Novogen Limited (NASDAQ:NVGN) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: N/A

Analysts' Ratings History for Novogen Limited (NASDAQ:NVGN)
Show:
DateFirmActionRatingPrice TargetDetails
9/27/2016HC WainwrightReiterated RatingBuyView Rating Details
(Data available from 2/25/2015 forward)

Earnings

Earnings History for Novogen Limited (NASDAQ:NVGN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Novogen Limited (NASDAQ:NVGN)
Current Year EPS Consensus Estimate: $-0.02 EPS
Next Year EPS Consensus Estimate: $-0.02 EPS

Dividends

Dividend History for Novogen Limited (NASDAQ:NVGN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Novogen Limited (NASDAQ:NVGN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Novogen Limited (NASDAQ:NVGN)
DateHeadline
seekingalpha.com logoNovogen nabs $3M grant to fund new cancer therapies; shares up 5% (NASDAQ:NVGN)
seekingalpha.com - February 10 at 1:03 AM
us.rd.yahoo.com logo5:43 pm Novogen awarded grant of up to AUD $3 mln by the Australian federal government to fund development of a next-generation anti-tropomyosin program (NASDAQ:NVGN)
us.rd.yahoo.com - February 8 at 7:50 PM
publicnow.com logoAppendix 3B New (NASDAQ:NVGN)
www.publicnow.com - November 23 at 9:45 AM
streetinsider.com logoNovogen (NVGN) Acquires Australian Biotech Company Glioblast Pty (NASDAQ:NVGN)
www.streetinsider.com - November 2 at 6:51 PM
News IconNovogen (ASX: NRT; NASDAQ: NVGN) signs licensing deal with Genentech (NASDAQ:NVGN)
www.finnewsnetwork.com.au - November 2 at 6:51 PM
publicnow.com logoChange in Director's Interest New (NASDAQ:NVGN)
www.publicnow.com - November 2 at 10:04 AM
publicnow.com logoIn-licensing of GDC-0084 – Investor Presentation New (NASDAQ:NVGN)
www.publicnow.com - November 1 at 11:44 AM
publicnow.com logoConversion of convertible notes and issue of Options New (NASDAQ:NVGN)
www.publicnow.com - November 1 at 11:44 AM
stockhouse.com logoNovogen Acquires Privately-held Glioblast for AU$2.1M in Cash, Stock, Plus Milestones (NASDAQ:NVGN)
www.stockhouse.com - October 31 at 1:07 PM
News IconGenentech Offloads Brain Drug to Tiny Australian Biotech Novogen Limited for Bargain Price (NASDAQ:NVGN)
www.biospace.com - October 31 at 1:07 PM
prnewswire.com logoNovogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma (NASDAQ:NVGN)
www.prnewswire.com - October 31 at 1:07 PM
baystreet.ca logoNovogen Limited (NVGN) Down on Glioblast Purchase (NASDAQ:NVGN)
www.baystreet.ca - October 31 at 1:07 PM
seekingalpha.com logoNovogen ups commitment to brain cancer with acquisition of Glioblast and license of product candidate GDC-0084 from Genentech (NASDAQ:NVGN)
seekingalpha.com - October 31 at 1:07 PM
finance.yahoo.com logo1:20 am Novogen announces the licensing of GDC-0084; ready to enter a phase II clinical trial in glioblastoma multiforme (NASDAQ:NVGN)
finance.yahoo.com - October 31 at 1:07 PM
publicnow.com logoSEC Form 20F New (NASDAQ:NVGN)
www.publicnow.com - October 28 at 6:19 PM
publicnow.com logoAppendix 4G and Corporate Governance Statement New (NASDAQ:NVGN)
www.publicnow.com - October 26 at 9:55 AM
publicnow.com logoNotice of Annual General Meeting New (NASDAQ:NVGN)
www.publicnow.com - October 20 at 12:19 PM
publicnow.com logoAnnual Report for the year ended 30 June 2016 New (NASDAQ:NVGN)
www.publicnow.com - October 20 at 12:19 PM
publicnow.com logoIssue of unlisted options under ESOP New (NASDAQ:NVGN)
www.publicnow.com - October 20 at 12:19 PM
finance.yahoo.com logoConversion of Convertible Notes (NASDAQ:NVGN)
finance.yahoo.com - September 14 at 10:47 AM
News IconFDA Approves Investigational New Drug (IND) Application for Cantrixil (TRX-E-002-1) in Ovarian Cancer (NASDAQ:NVGN)
www.drugs.com - September 13 at 11:24 AM
News IconNovogen (NVGN) Boosted on Investigational Drug Application with FDA (NASDAQ:NVGN)
www.economiccalendar.com - September 12 at 6:13 PM
4-traders.com logoNovogen : FDA approves IND application for Cantrixil (NASDAQ:NVGN)
www.4-traders.com - September 12 at 11:06 AM
stockhouse.com logoNovogen Announces FDA Approves IND Application for Cantrixil in Ovarian Cancer (NASDAQ:NVGN)
www.stockhouse.com - September 12 at 11:06 AM
baystreet.ca logoNovogen (NVGN) Hikes on FDA Nod (NASDAQ:NVGN)
www.baystreet.ca - September 12 at 11:06 AM
publicnow.com logoFDA approves IND application for Cantrixil (NASDAQ:NVGN)
www.publicnow.com - September 12 at 11:06 AM
publicnow.com logoResignation/appointment of Company Secretary (NASDAQ:NVGN)
www.publicnow.com - September 12 at 11:06 AM
finance.yahoo.com logoUS FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer (NASDAQ:NVGN)
finance.yahoo.com - September 12 at 11:06 AM
finance.yahoo.com logoNovogen secures key US drug study approval (NASDAQ:NVGN)
au.finance.yahoo.com - September 12 at 11:05 AM
publicnow.com logoNovogen appoints Scientific Advisory Board to guide development of oncology pipeline (NASDAQ:NVGN)
www.publicnow.com - September 5 at 10:42 AM
publicnow.com logoAppendix 4E and Full Year Statutory Accounts (NASDAQ:NVGN)
www.publicnow.com - August 30 at 9:52 AM
publicnow.com logoNovogen appoints Key Management Personnel to drive transition to a development-focused organisation (NASDAQ:NVGN)
www.publicnow.com - August 29 at 11:02 AM
publicnow.com logoNovogen Submits IND Application to the US FDA for Cantrixil in Ovarian Cancer (NASDAQ:NVGN)
www.publicnow.com - August 15 at 8:46 AM
nasdaq.com logoNovogen Submits IND Application For Cantrixil In Ovarian Cancer To FDA (NASDAQ:NVGN)
www.nasdaq.com - August 12 at 9:46 AM
finance.yahoo.com logoNovogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer (NASDAQ:NVGN)
finance.yahoo.com - August 11 at 9:46 AM
4-traders.com logoNovogen : Graham Kelly seeks cash for new Australia oncology biotech (NASDAQ:NVGN)
www.4-traders.com - June 29 at 6:27 PM
finance.yahoo.com logoNovogen Patent Covering Anisina(TM) Has Proceeded to Grant (NASDAQ:NVGN)
finance.yahoo.com - June 13 at 8:30 PM
publicnow.com logoNovogen Patent Covering Anisina Has Proceeded to Grant (NASDAQ:NVGN)
www.publicnow.com - June 13 at 7:09 PM
publicnow.com logoEdison Investment Research Report maintains valuation as Novogen resumes 100% ownership of Cantrixil (NASDAQ:NVGN)
www.publicnow.com - May 9 at 9:38 PM
prnewswire.com logoNovogen Provides Update On Development Of Cantrixil - PR Newswire (press release) (NASDAQ:NVGN)
www.prnewswire.com - May 3 at 2:24 PM
News IconNovogen Limited Ads (NASDAQ:NVGN) Shorted Shares Decreased By 27% - B.O.D.Y Confidential (NASDAQ:NVGN)
www.bodyconfidential.com - May 3 at 2:24 PM
finance.yahoo.com logoNovogen Provides Update On Development Of Cantrixil (NASDAQ:NVGN)
finance.yahoo.com - May 1 at 10:43 PM
seekingalpha.com logoAnavex Life Sciences: Miracle Drug With A Toxic Financing Set For A Severe Decline In Price - Seeking Alpha (NASDAQ:NVGN)
seekingalpha.com - April 27 at 2:54 PM
publicnow.com logoCantrixil (TRXE-002-1) Abstract (AACR Annual Meeting 2016) (NASDAQ:NVGN)
www.publicnow.com - April 17 at 8:36 PM
finance.yahoo.com logoNovogen appoints new CEO (NASDAQ:NVGN)
au.finance.yahoo.com - December 9 at 7:56 PM
finance.yahoo.com logoNovogen Appoints Dr James Garner as Chief Executive Officer (NASDAQ:NVGN)
finance.yahoo.com - December 9 at 4:59 PM
finance.yahoo.com logoNOVOGEN LTD Financials (NASDAQ:NVGN)
finance.yahoo.com - December 8 at 1:16 PM
finance.yahoo.com logoNovogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial (NASDAQ:NVGN)
finance.yahoo.com - November 23 at 7:38 PM
finance.yahoo.com logoNovogen Patent Covering Cantrixil and Trilexium Accepted in Australia (NASDAQ:NVGN)
finance.yahoo.com - November 11 at 7:04 PM
finance.yahoo.com logoPreclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina (NASDAQ:NVGN)
finance.yahoo.com - November 10 at 5:34 PM

Social

What is Novogen Limited's stock symbol?

Novogen Limited trades on the NASDAQ under the ticker symbol "NVGN."

Who owns Novogen Limited stock?

Novogen Limited's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.80%).

How do I buy Novogen Limited stock?

Shares of Novogen Limited can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Novogen Limited stock cost?

One share of Novogen Limited stock can currently be purchased for approximately $1.72.

Novogen Limited (NASDAQ:NVGN) Chart for Saturday, February, 25, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Novogen Limited (NASDAQ:NVGN)

Earnings History Chart

Earnings by Quarter for Novogen Limited (NASDAQ:NVGN)

Dividend History Chart

Dividend Payments by Quarter for Novogen Limited (NASDAQ:NVGN)

Last Updated on 2/25/2017 by MarketBeat.com Staff